Marco Gymnopoulos, Ph.D. joined Tanabe Research Laboratories USA, Inc., in 2015. He has over 15 years’ experience in cancer research and nearly ten years in the field of antibody-drug conjugates. His group at Tanabe is responsible for ADC target identification, validation and preclinical assessment. Marco was previously at Ambrx and other biotech companies in the US. He received his MS in Biology from the University of Göttingen in Germany and was awarded his Ph.D. in Neurobiology from the Max-Planck Institute of experimental Medicine in Göttingen. For 5 years he worked as a post-doc in Peter K. Vogt’s lab at The Scripps Research Institute in the department of Molecular Medicine-Oncovirology.